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Dear Editor,
Inhibition of the epidermal growth factor receptor 
(EGFR) is a new strategy in treatment of a variety of 
solid tumors, such as colorectal carcinoma, non-small 
cell lung cancer, squamous cell carcinoma of the 
head and neck, and pancreatic cancer (1). Cetuximab 
is a chimeric human-murine monoclonal antibody 
against EGFR. Cutaneous side effects are the most 
common adverse reactions occurring during epider-
mal growth factor receptor inhibitors (EGFRI) therapy. 
Papulopustular rash (acne like rash) develop with 80-
86% patients receiving cetuximab, while xerosis, ec-
zema, fissures, teleangiectasiae, hyperpigmentations, 
and nail and hair changes occur less frequently (2). 
The mechanism underlying these skin changes has 
not been established and understood. It seems EGFRI 
alter cell growth and differentiation, leading to im-
paired stratum corneum and cell apoptosis (3-5).
An abdominoperineal resection of the rectal 
adenocarcinoma (Dukes C) was performed on a 43-
year-old female patient. Following surgery, adjuvant 
chemo-radiotherapy was applied. After two years, 
the patient suffered a metastatic relapse. Abdominal 
lymphadenopathy was detected on multi-slice com-
puter tomography (MSCT) images, with an increased 
value of the carcinoembryonic antigen (CEA) tumor 
marker (maximal value 57 ng/mL). Hematological 
and biochemical tests were within normal limits, so 
first-line chemotherapy with oxaliplatin and a 5-fluo-
rouracil (FOLFOX4) protocol was introduced. A wild 
type of the KRAS gene was confirmed in tumor tissue 
(diagnostic prerequisite for the introduction of EG-
FRI) and cetuximab (250 mg per m2 of body surface) 
was added to the treatment protocol. The patient re-
sponded well to the treatment with confirmed partial 
regression of the tumor formations. 
Three months after the patient started using ce-
tuximab, an anti-EGFR monoclonal antibody, the 
patient presented with a papulopustular eruption in 
the seborrhoeic areas (Figure 1) and eczematoid reac-
tions on the extremities with dry, scaly, itchy skin (Fig-
ure 2). Furthermore, hair and nail changes gradually 
developed, culminating with trichomegaly (Figure 
3) and paronychia (Figure 4). The patient was treated 
with oral antibiotics (tetracycline) and a combination 
of topical steroids with moisturizing emollients due 
to xerosis, without reduction of EGFRI therapy and 
with a very good response. Trichomegaly was regu-
larly sniped with scissors. Nail fungal infection was 
ruled out by native examination and cultivation, so 
antiseptics and corticosteroid ointments were intro-
duced for paronychia treatment. 
Figure 1. Papulopustular rash. Figure 2. Xerosis of the skin. 
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During the above-mentioned therapy, apart from 
skin manifestations, iatrogenic neutropenia grade IV 
occurred, with one febrile episode, and because of 
this, the dose of cytostatic drugs was reduced. After 
10 months of therapy, progression of the disease oc-
curred with lung metastases, so EGFRI therapy was 
discontinued and the patient was given second-line 
chemotherapy for metastatic colorectal carcinoma. 
This led to gradual resolution of all aforementioned 
cutaneous manifestations.
Since the pathogenesis of skin side-effects due to 
EGFRI is not yet fully understood, there are no strict 
therapy protocols. Therapy is mainly based on clinical 
experience and follows the standard treatments for 
acne, rosacea, xerosis, paronychia, and effluvium. The 
therapeutic approach for papulopustular exanthema 
includes topical and systemic antibiotics for their an-
timicrobial as well as anti-inflammatory effect, some-
times in combination with topical steroids. Topical 
application of urea cream with K1 vitamin yielded 
positive results in skin-changes prevention during 
EGFRI therapy, especially with xerosis, eczema, and 
pruritus (6). Hair alterations in the form of effluvium 
are usually tolerable, and if needed a 2% minoxidil 
solution may be applied. Trichomegaly or abnormal 
eyelash growth can lead to serious complications, so 
ophthalmologic examination is needed. At the begin-
ning of the growth, regular lash clipping may reduce 
possibility of corneal abrasion (7,8). Nail changes can 
just be a cosmetic problem (pigmentary changes, 
brittle nails), and in the occurrence of paronychia or 
onycholysis (of several or all nails) they result in high 
morbidity and impair daily activities. Nail manage-
ment should be started as soon as possible because 
of slow nail growth and the relatively long half-life of 
EGFRI. Combination of topical iodide, corticosteroids, 
antibiotics, and antifungals with avoidance of nail 
traumatization will yield the best results (9). 
EGFRI are potentially life prolonging therapies, 
and our goal as dermatovenereologists is to provide 
optimal patient care and improve their quality of life 
in a multidisciplinary collaboration with oncologists, 
radiotherapists, and ophthalmologists.
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